Natalizumab (Tysabri)

Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of neuroradiology : AJNR 2010-10, Vol.31 (9), p.1588-1590
Hauptverfasser:	SELEWSKI, D. T, SHAH, G. V, SEGAL, B. M, RAJDEV, P. A, MUKHERJI, S. K
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antibodies, Monoclonal, Humanized Biological and medical sciences Brain - drug effects Brain - immunology Cell Adhesion - drug effects Cell Adhesion - immunology Cell Migration Inhibition - drug effects Cell Migration Inhibition - immunology Humans Investigative techniques, diagnostic techniques (general aspects) Leukocytes - drug effects Leukocytes - immunology Medical sciences Models, Immunological Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Natalizumab Nervous system Pharmacology Vignette Radiodiagnosis. Nmr imagery. Nmr spectrometry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
ISSN:	0195-6108 1936-959X
DOI:	10.3174/ajnr.A2226